The plasma fraction market has witnessed significant growth and innovation, with increasing demand for plasma-derived therapies addressing a wide range of medical conditions. This article explores the current market trends, segmental insights, and recent developments that are shaping the future of plasma-derived medicines.
Plasma Fraction Market Overview
The global plasma fraction market was valued at US$ 32.75 billion in 2023 and is projected to reach US$ 72.86 billion by 2034, growing at a CAGR of 7.54% from 2024 to 2034. This expansion is largely driven by the rising demand for plasma-derived medicines used in treating conditions like rabies, tetanus, shock, and trauma. As these life-threatening diseases continue to pose challenges, the need for effective therapeutic solutions derived from plasma is growing, fueling the market’s rapid development.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5304
Segmental Insights
By Type
In 2023, the immunoglobulin segment led the market, capturing the highest share. Plasma-derived immunoglobulin plays a pivotal role in the treatment of autoimmune inflammatory diseases, especially in conditions where the body requires recovery after an infectious attack like COVID-19. Immunoglobulins are essential for treating rare conditions, such as primary immunodeficiency, where they often represent the only viable treatment option.
The coagulation factors segment is anticipated to grow at the fastest pace during the forecast period. These products are crucial for treating blood clotting disorders such as hemophilia and Von Willebrand’s disease, leading to the increased demand for plasma-derived therapies in these areas.
By Application
The hospital segment dominated the plasma fraction market in 2023, thanks to the extensive use of plasma protein to treat a range of conditions in hospital settings. Plasma proteins are vital in managing trauma, burns, animal bites, shocks, major surgeries, hepatitis, RH incompatibility, organ transplants, pediatric HIV, and liver diseases.
Meanwhile, the retail pharmacy segment is expected to experience the fastest growth during the projected period. This growth is driven by a steady rise in human plasma donations and an increasing number of patients eligible for plasma-derived therapies, enhancing both supply and retail sales.
Industry Announcements
Dr. Ranjeet S. Ajmani, CEO of Aegros Asia, outlined a bold vision to transform plasma fractionation across Asia and other developing regions. His focus is on creating sustainable plasma fractionation models using the HeamaFrac process, addressing the critical issue of over 2 million liters of plasma being wasted annually in Asia. Through partnerships with blood centers, regulators, and local and international organizations, Aegros aims to provide consistent access to safe plasma-derived medicines and improve the quality of life for patients in these regions.
Recent Developments
- Grifols Collaboration with Orange Business:
In September 2024, Grifols, a leading global healthcare company, joined forces with Orange Business to build a state-of-the-art data center for plasma derivative facilities in Egypt. The collaboration is set to enhance the sustainable supply of critical therapeutics for life-threatening diseases, ensuring that more patients have access to life-saving treatments. - Kedrion Biopharma’s Commercialization Agreement:
In July 2024, Kedrion Biopharma Inc. announced a long-term partnership with Biotest AG for the commercialization and distribution of Yimmungo®, an immunoglobulin therapy approved by the FDA in June 2024. This agreement strengthens Kedrion’s presence in the market and expands access to advanced immunoglobulin treatments.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5304
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
